← Home / IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Stock Analysis

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

IOVA
IOVA · Healthcare • Biotechnology
8.71 +1.10%
Track IOVA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IOVA price is:
52W Range Position
96%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-09-04 03:56 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Strong / Negative / Pressured / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
No setup-specific trigger is available; nearest structural resistance is shown.
9.35
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
6
●
Financial Results
HIGH
IOVA reports financial results
On August 6, 2026, Iovance Biotherapeutics, Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
First Quarter 2026
(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.
8-K Filing • SEC EDGAR
What's Driving IOVA?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is strong. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
69.3
Price Chart
IOVA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-09-03
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$3.9B
Company size
EV
$3.5B
Debt-adjusted value
P/S
12.0
Premium
P/B
5.3
Balanced
EV/Sales
10.8
Premium
EV/EBIT
-20.6
Not meaningful
P/FCF
-20.8
Not meaningful
FCF Yield
-4.81%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
99.31M
↗ Strong
📈 Net Income
-47.31M
↘ Negative
🧮 EPS (Basic)
-0.11
↘ Negative
IOVANCE BIOTHERAPEUTICS, INC.
Healthcare • Biotechnology
You Might Also Like